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studied include age (<45 vs. ≥45 years), hypertension, diabetes, congestive heart 
failure (CHF, history of heart failure or ejection fraction [EF] ≤40%), gender,  
prior MI, final diagnosis, and MI type. RESULTS: Of 1166 consecutive patients, 
1073 underwent CAG, considered eligible: normal coronaries, 113 (10.5%); leaving 
960 patients with CAD (MI [289, 30.1%], UA [604, 62.9%], Undetermined ACS [32, 
3.3%], CSA [35, 3.7%]); 30% patients were diabetic. Proportion of hypertensive 
patients was significantly higher among diabetics (57.7% vs. 34.9% non-diabetics, 
P<0.001). The presence of CHF in the diabetic as well as non-diabetic patients 
was similar. For all patients with CAD, around 40% had SVD on CAG; for 
diabetics, 35% patients had TVD whereas the proportion was only 24% among 
non-diabetics. In the linear stepwise regression, age ≥45 years, presence of CHF 
and diabetes showed significant positive correlation with the severity of CAD 
(p<0.05). CONCLUSIONS: Clustering of several cardiovascular risk factors at 
presentation may lead to the worse prognosis in patients with CAD from India. 
Findings from this study ascertain more severe angiographic findings in diabetic 
patients than that in non-diabetic controls regarding the severity of CAD.  
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OBJECTIVES: To explore the association between race, comorbidities, and 
therapy use among patients with heart failure (HF) in a contemporary Medicaid 
population. METHODS: Medical/prescription/enrollment records from the 
Maryland State Medicaid Managed Care Organization/Fee-for-services, ages 18-
64, non-dual enrolled, with HF diagnosis between July 1, 2005 to December 31, 
2009, followed at least 3 months. Diagnosis for HF defined as earliest encounter 
claim that included ICD-9 code 428.xx. Comorbidity diagnosis determined 
between earliest claim and within three months post-HF diagnosis. First-line 
therapies ascertained using pharmacy claims with first-date-of-service between 
HF diagnosis and the end of follow up. Variation in comorbidities and therapy 
use across race/ethnicity is described. RESULTS: Among 15,764 HF patients, 60% 
(n=9,388) were black, 33% (n=5,158) white, 6% (n=919) other, 2% (n=299) Hispanic. 
Over half were female (55%); 72% older than 44 years. Prevalence in 
race/ethnicity: COPD (40% white, 22% black, 20% other, 11% Hispanic; p<0.001), 
stroke (20-22%; p=0.17), renal dysfunction (38% Hispanic, 30% black, 27%other, 
22% white; p<0.001), diabetes (38-42%; p=0.04), psychological disorder (65% white, 
52% black, 46% other, 37% Hispanic; p<0.001), hyperlipidemia (44% white, 39% 
Hispanic, 31% other, 33% black; p<0.001), chronic ischemic heart disease (47% 
white, 41% black/Hispanic/other; p<0.001), hypertension (76% black, 72% 
Hispanic, 68% white, 67% other; p<0.001), other cardiovascular disease (76-80%; 
p=0.17). Excluding other cardiovascular disease, the median number of comorbid 
conditions was 3 in each race/ethnicity. Among black, white, Hispanic and other, 
only 5.8%, 4.4%, 9.0%, and 7.3% had zero comorbidities, and 14.2%, 11.4%, 12.4%, 
15.8% had only one comorbidity, respectively. Hispanics (53%) were less likely 
than blacks (62%), whites (61%), or others (57%) to be prescribed ACE-
inhibitor/ARB, beta-blockers, aldosterone antagonists, and/or other 
cardiovascular drugs including combination nitrates/hydralazine (p<0.001). 
CONCLUSIONS: Whites were most likely to be diagnosed with COPD, 
psychological disorders, hyperlipidemia, and chronic ischemic heart disease. 
Hypertension was most likely among Blacks, and renal dysfunction most likely 
among Hispanics.  
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OBJECTIVES: Increasing prevalence of heart failure, increasing enrollment in 
state programs, sparse literature on population-based heart failure studies, and 
the associations between lower socioeconomic status and increased comorbidity 
burden necessitate an examination of the prevalence of HF comorbidities in a 
contemporary Medicaid population. METHODS: Medical/prescription/enrollment 
records from the Maryland State Medicaid Managed Care Organization/Fee-for-
services, ages 18-64, non-dual enrolled, with HF diagnosis between July 1, 2005 to 
December 31, 2009, followed at least 3 months. Diagnosis for HF defined as 
earliest encounter claim that included ICD-9 code 428.xx. Comorbidity diagnoses 
determined between earliest claim and within three months post-HF diagnosis. 
The frequencies and cross-frequencies of the selected comorbidities are 
examined. RESULTS: Among 15,764 HF patients, 60% (n=9,388) were black, 33% 
(n=5,158) white, 6% (n=919) other, 2% (n=299) Hispanic. Over half were female 
(55%); 29% were ages 18-44, 36% ages 45-54, and 36% ages 55-64. The most 
common comorbidity was other cardiovascular disease (CVD, 78%), followed by 
hypertension (73%), psychological disorder (57%), chronic ischemic heart disease 
(43%), diabetes (41%), hyperlipidemia (37%), chronic obstructive pulmonary 
disease (28%), renal dysfunction (28%), and stroke (21%). This pattern persisted 
within any particular comorbidity group. Excluding hypertension and other CVD: 
10% of patients had zero comorbidities, 20% had only one, 70% had multiple 
comorbidities; 0.7% (n=114) had every comorbidity above. The median number of 
comorbidities was 2; median being 4 if hypertension and other CVD are included. 
CONCLUSIONS: An overwhelming majority of HF patients enrolled in Maryland 
Medicaid have multiple comorbidities. The prevalence of any comorbidity above 
was no less than 21%; the most prevalent comorbidities being hypertension, 
other CVD, and psychological disorder. Our findings call attention to the level 
comorbidity in a high-risk Medicaid population, reflecting a demographic largely 
under-represented in large scale studies or clinical trials. Future research should 
identify clinical and hospitalization issues associated with prevalent disease in 
this population.  
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OBJECTIVES: Increasing prevalence of heart failure (HF), increasing enrollment in 
state programs, sparse literatures on population-based heart failure studies, and 
the burden of hospitalization among Medicaid patients necessitate an analysis of 
risk factors for heart failure hospitalization in a contemporary Medicaid population. 
METHODS: Claims from Maryland State Medicaid, for 14,149 non-dually enrolled, 
18-64 year olds with a diagnosis for HF between 7/1/05-12/31/09, followed for at 
least six months. We examine the effects of comorbidity and first-line therapy use 
on the risk of any hospitalization after HF diagnosis. Multivariate Weighted Cox 
Regressions were used to address non-proportional risk of hospitalization over the 
follow-up period. We report numbers needed to treat with first-line therapy to 
prevent one hospitalization annually. RESULTS: Most patients were >45 years (71%), 
female (56%), and black (60%). Use prevalence was: beta-blockers (26%), ACE-
inhibitors/ARB (29%), aldosterone antagonists (AA, 5%), and others including 
nitrates+hydralazine (37%). Nearly all (98%) were diagnosed with one or more 
comorbidities. Relative risk (95% CI) for any hospitalization was 1.43 (1.36-1.51) renal 
dysfunction, 1.40 (1.31-1.50) other cardiovascular, 1.33 (1.26-1.40) COPD, 1.28 (1.22-
1.35) chronic ischemic heart disease, 1.27 (1.20-1.34) stroke, 1.26 (1.20-1.32) diabetes, 
1.11 (1.05-1.17) hypertension, 0.81 (0.77-0.85) hyperlipidemia, 0.77 (0.73-0.81) 
psychological disorder; 0.77 (0.73-0.81) ACE inhibitor/ARB, 0.83 (0.79-0.87) beta-
blocker, 0.76 (0.72-0.80) other cardiovascular drugs. AA and/or nitrates+hydralazine 
combination had no impact. The C-statistic for predicted 1-year hospitalization risk 
within the sample was 0.80. Numbers needed to treat to prevent one hospitalization 
annually: 12 ACE-inhibitor/ARB, 15 beta-blockers, or 11 other cardiovascular drugs. 
CONCLUSIONS: We elicit the specific risk attributable to lead risk factors in HF 
patients enrolled in Medicaid plans, and show certain disease modifying therapies 
can quantifiably mitigate risk of hospitalization. Growing ranks of state Medicaid 
plans and other entitlement programs call for more deliberate, proactive and cost-
effective disease and risk management of plan enrollees.  
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OBJECTIVES: Venous thromboembolism (VTE) includes deep-vein thrombosis 
(DVT) and pulmonary embolism (PE), with a considerable risk of recurrence and 
mortality. This study examined the recurrence rate and associated risk factors in 
hospitalized patients with acute VTE in the US clinical practice setting. 
METHODS: Adult patients with VTE were selected from the linked MarketScan 
and Hospital Discharge database in an inpatient setting between 07/01/2006-
12/31/2011. The first hospitalization with a diagnosis of VTE (ICD-9-CM: 451-453, 
671.3, 671.4, 671.9, 415.1, 673.2, or 673.8) was designated as index hospitalization. 
Patients were required to have at least 6 months continuous enrollment and 
have no VTE diagnosis in the 6 months prior to index hospitalization. Patients 
were followed until the earliest of VTE recurrence, death, disenrollment, or the 
end of study. VTE recurrence was defined as re-hospitalization with VTE at least 
1 day after discharge from index hospitalization. Cox regression was used to 
model time to recurrence and examine demographic and clinical factors 
associated with recurrence. RESULTS: A total of 957 patients were eligible for the 
study, including 570 patients with DVT only (59.6%); 237 with PE only (24.7%); and 
150 with both DVT and PE (15.7%). Mean age was 62.8 years (SD=15.2), and 432 
were male (45.1%). Mean follow-up time was 23.1 months. During follow-up, 146 
patients recurred, with a recurrence rate of 15.3%. The average time to 
recurrence was 20.1 months (median=15.4). Number of comorbid conditions as 
measured by Charlson Comorbidity Index was independently associated with 
increased risk for VTE recurrence (hazard ratio [HR]: 1.12, 95%CI=1.05 – 1.20). 
CONCLUSIONS: More than 15% of hospitalized patients with acute VTE recurred 
during an average follow-up period of 23 months in the real clinical setting. 
Comorbidities were associated with increased risk for recurrence. Further 
research needs to examine recurrence and its economic outcomes associated 
with VTE treatment patterns.  
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OBJECTIVES: High-dose statin therapy has been reported to be associated with 
increased risk of side effects, which may reduce treatment adherence and 
impact cardiovascular (CV) outcomes. This study assessed association between 
initial statin dose and treatment adherence and persistence and its impact on CV 
outcomes in the overall and sub-population with prior CV events. METHODS: An 
observational, retrospective study was conducted in a UK linked database (CPRD) 
comprising primary care, secondary care (Hospital Episode Statistics), and 
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mortality data. Study cohort was statin-naïve patients initially prescribed statin 
therapy from January 2003–July 2011, and registered within the practice for ≥1 
year preceding statin initiation. High-dose was defined as simvastatin 80mg, 
fluvastatin 80mg, atorvastatin>20mg, rosuvastatin>10mg. Adjusted Cox 
regression models were used to predict factors associated with discontinuation 
and CV event risk. RESULTS: Only 2% (4,744/218,808) of patients started on a 
high-dose statin; 4,399/4,744, (93%) on atorvastatin, a third taking atorvastatin 
80mg. Adherence was high based on prescribed medication possession ratio for 
high- (0.96, SD:0.08) and low-dose (0.95, SD:0.10) initiation. Initial dose was not a 
predictor of discontinuation in the overall population (HR:0.96 95%CI:0.91-1.02), 
but in patients with CV history, high-dose initiation was associated with lower 
discontinuation risk (HR:0.87 95%CI 0.78-0.96). In the overall population 
increased CV event rates were associated with initiation of high-dose statin 
(OR:2.07 95%CI:1.78-2.41), greater Framingham risk (OR:1.50 95%CI 1.44-1.56), 
prior unstable angina (OR:3.06 95%CI:2.53-3.71), heart failure (OR:2.73 95%CI:2.13-
3.51), and myocardial infarction (MI) (OR:4.29 95%CI:3.56-5.17). In the CV sub-
group, only prior MI was associated with increased CV event risk (OR:1.26 
95%CI:1.03-1.55). CONCLUSIONS: Initial high-dose statin was not associated with 
lower adherence or persistence; among patients with CV history, risk of 
discontinuation was significantly lower. The association of initial high-dose 
statin treatment with higher CV event rates may be due to background risk 
factors leading to use of high-dose statin.  
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OBJECTIVES: Many new catheter ablation (CA) methods based on pulmonary 
vein isolation (PVI) have been developed. The aim of this study was to assess the 
benefits and harms of additional linear ablation with PVI/ circumferential 
pulmonary vein ablation (CPVA) in comparison with PVI/CPVA in patients with 
AF. METHODS: Ovid-Medline, Ovid-EMBASE, Cochrane library, and seven Korean 
medical databases were searched to identify studies through May, 2012. To 
assess the quality of randomized controlled trials (RCTs), the Cochrane risk of 
bias tool was used. Data were independently extracted by two reviewers using a 
standardized form. Disagreements between reviewers were resolved by 
discussion and consensus. The dichotomous data were presented as pooled 
relative risk (RR) with 95% confidence intervals (CI) using random-effects model. 
RESULTS: A total of 12 RCTs (1,226 patients) were included and of poor quality. 
Differences between groups of all-cause mortality were not reported in 12 RCTs. 
PVI/CPVA plus additional linear ablation, in comparison with PVI/CPVA, 
increased freedom from atrial tachycardia (AT)/AF (RR 1.10, 95% CI 0.97-1.25, 
I2=64%) in 12 RCTs, but there was insignificant and moderate heterogeneity 
among trials. The RR of stroke, transient ischemic attack (TIA) or thrombo-
embolic events between both groups was 0.75 (95% CI 0.20-2.81, I2=0%). Fewer 
complications and adverse events were reported in the trials and there were no 
differences. CONCLUSIONS: The results of meta-analysis showed a trend of favor 
of PVI/CPVA plus additional linear ablation for freedom from AT/AF, and similar 
result in the rates of stroke, TIA or thrombo-embolic events. There is limited 
evidence to suggest that PVI/CPVA plus additional linear ablation may be a better 
treatment option compared to PVI/CPVA in patients with AF. Well-designed, 
adequately powered, and long-term clinical trials are warranted.  
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OBJECTIVES: Statin treatment has been shown to be effective in secondary 
prevention for vascular events among patients with established cardiovascular 
diseases (CVD). However, its effectiveness of primary prevention for CVD on the 
elderly is unknown. The aim of this study was to examine whether statins are 
effective in reducing CVD risk among the elderly without medical history of CVD. 
METHODS: We used population-based National Health Insurance Database to 
conduct a retrospective cohort study. We identified 5374 lipid-lowering drugs 
users aged over 55 years old who were first-time users of statin or lowering 
cholesterol medications for primary prevention purpose between year 2000 and 
2003. We used cox proportional hazard model to analyze the risk of coronary 
artery heart disease, cerebrovascular disease or peripheral arterial occlusion 
disease during follow-up time. Interaction terms of age and statins were 
included in the model to examine the heterogeneous effect of statins across age 
groups. We used propensity score to adjust the potential self-selection effect of 
using statins on CVD risks. RESULTS: During the 6-10-year follow-up period, 2944 
patients experienced new-onset CVD. The statins users had lower risk for CVD 
events compared to non-statin lipid-lowering drug users (adjusted hazard ratio 
0.86; 95% CI, 0.78-0.93; P=.0005). The age/statin interaction term was not 
statistically significant (P=.5562). CONCLUSIONS: Statin therapy was effective in 
preventing new onset of CVD among the elderly patients.  
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OBJECTIVES: Statins are the first recommended pharmacotherapy to lower LDL-
C, with rosuvastatin as the most potent available statin. Clinical outcomes are 
improved with statin use in patients at high risk for cardiovascular disease 
(CVD). Guidelines recommend specific LDL-C goals for patients dependent on 
pre-existing CV risk factors. The present analysis examined LDL-C goal 
attainment in US patients at high CV risk treated with rosuvastatin 
monotherapy. METHODS: In a retrospective study using the GE Healthcare 
Centricity database, patients who received a prescription (Rx) for rosuvastatin 
monotherapy (index Rx) between January 1, 2008 and December 31, 2010 were 
identified. Included were patients with coronary heart or atherosclerotic vascular 
disease, ≥1 LDL-C measurement between 3 months and 1 year post-index Rx, 
and medical records for 1 year prior to and following index Rx. Proportions of 
patients attaining LDL-C <70 and <100 mg/dL were estimated for all patients, as 
well as by rosuvastatin daily dose. RESULTS: Of 6004 patients (age=66 yrs [SD 10]; 
56% males), 15%, 39%, 29%, and 17% received Rxs for 5, 10, 20 and 40 mg 
rosuvastatin, respectively. Overall, mean follow-up LDL-C was 89 mg/dL (SD 37); 
only 32% of patients had an LDL-C <70 mg/dL and 72% had an LDL-C <100 mg/dL. 
By increasing dose, mean LDL-C decreased and proportions at goal generally 
increased. For goal of LDL-C <70 mg/dL, 39% of all patients had a follow-up LDL-C 
≥20 mg/dL above this goal, while 16% had an LDL-C ≥20 mg/dL above the 100 
mg/dL goal. CONCLUSIONS: The proportion of patients at high CV risk achieving 
recommended LDL-C goals with rosuvastatin monotherapy was suboptimal, with 
more than 63% not achieving the current optional LDL-C goal of <70 mg/dL 
across doses. This suggests a treatment gap and more effective lipid-lowering 
strategies, such as aggressive dose titration or additional therapies, are 
warranted in this high-risk population.  
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OBJECTIVES: Despite evidence from randomized controlled trials which show 
that treatment with high-intensity statins can result in an additional 16% 
reduction in CVD events compared to moderate-dose statins, only 20-25% of very 
high risk patients receive high-intensity statins. Geographic variation in statin 
prescribing, in addition to the existence of a “treatment risk paradox” in which 
complex patients with apparently more to gain from treatment are less likely 
treated, may be associated with this low rate. Our objective is to determine 
whether there is an association between patient complexity and the intensity of 
statin treatment following acute myocardial infarction (AMI) by geographical 
region. METHODS: This was a retrospective cohort study of 124,397 Medicare 
patients with fee-for service Part A and B, and the Part D benefit who were 
hospitalized with AMI in 2008 or 2009. Patient complexity was defined by the 
presence or absence of diabetes, heart failure, and chronic kidney disease in the 
year prior to admission. Treatment with atorvastatin 40,80mg; and rosuvastatin 
20,40mg in the first thirty days post discharge was defined as high-intensity; 
other statin treatment as low/moderate intensity, and the absence of a fill as no 
treatment. Area treatment rates (ATRs) adjusted for baseline patient 
characteristics were calculated and grouped into quintiles of “no treatment”, 
“low/moderate”, and “high” treatment areas. Tables were generated calculating 
statin intensity treatment rates by comorbidity-based AMI patient complexity. 
RESULTS: Those patients with no evidence of any complex conditions have the 
lowest "no treatment" rates (36.4%), while the highest "no treatment" rates occur 
among those with all three conditions (54.2%). Substantial geographic variation 
in the intensity of statin treatment within patient complexity subgroups is 
revealed using the ATR method. CONCLUSIONS: Despite guidelines promoting 
the use of high-intensity statins, more complex patients are less likely to be 
treated and treatment discretion is revealed in the geographic variation.  
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OBJECTIVES: Atrial fibrillation (AF) is an irregular and often rapid heart rate that 
commonly causes poor blood flow to the body. Dabigatran and Warfarin have 
shown safety and efficacy for treatment of AF. The objective of this study was to 
conduct meta-analysis and present evidence for safety of Dabigatran versus 
Warfarin for treatment of AF. METHODS: For this meta-analysis we included 
randomized controlled trials (RCTs) evaluating Dabigatran for the treatment of 
AF. We included studies that were: 1) a RCT in humans; 2) an investigation of 
patients with nonvalvular atrial fibrillation; 3) an evaluation of dabigatran 
compared with warfarin or each other; and 4) a report of results of stroke or 
systemic emboli and major bleeding. A systematic literature search for 
dabigatran trials was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar, and Cochrane. Data was collected for the study size, 
interventions, year and total bleeding events. For meta-analysis, random effects 
and fixed effects models were used to obtain cumulative statistics. RESULTS: 
Two RCTs with a total of 12,268 patients were identified. The pooled event rate 
for Dabigatran for total bleeding events was 31.9% (95% CI 31%-33%). The pooled 
response rate for Warfarin for total bleeding events was 35.1% (95% CI 34%-37%). 
The cumulative relative risk for total bleeding events with Dabigatran versus 
Warfarin was 1.1 (95% CI 1.08-1.12). CONCLUSIONS: Meta-analysis shows 
Dabigatran has a slightly lower rate of total bleeding events compared to 
Warfarin.  
